| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hesham Salem, Ebtihal Samir, Dina Z Mazen, Hoda Madian, Alshimaa E Elkhateeb, Manar Elaraby, Manar I Rasekh, Aliaa Gama. Corrigendum to "Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma" [Spectrochim. Acta A: Mol. Biomol. Spectrosc. 274 (2022) 121105]. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. vol 314. 2024-03-30. PMID:38554695. |
corrigendum to "spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma" [spectrochim. |
2024-03-30 |
2024-04-02 |
human |
| Anna Czyż, Alicja Zakrzewska-Sito, Julita Kuczyńsk. A Review of Advances in Bioanalytical Methods for the Detection and Quantification of Olanzapine and Its Metabolites in Complex Biological Matrices. Pharmaceuticals (Basel, Switzerland). vol 17. issue 3. 2024-03-28. PMID:38543189. |
one of these drugs is olanzapine, which has an effective effect on the productive symptoms of schizophrenia while having an almost minimal potential to cause extrapyramidal syndrome. |
2024-03-28 |
2024-03-30 |
Not clear |
| Yong Zhao, Yifan Li, Jing Du, Chuanlong Fang, Wansheng Li, Mengyu Lv, Yue Wu, Kai Wang, Tingting Wu, Yanghua Tian, Juanjuan Zhan. Modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: Potential benefits of olanzapine. Schizophrenia research. Cognition. vol 36. 2024-03-12. PMID:38469136. |
modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: potential benefits of olanzapine. |
2024-03-12 |
2024-03-14 |
Not clear |
| Yong Zhao, Yifan Li, Jing Du, Chuanlong Fang, Wansheng Li, Mengyu Lv, Yue Wu, Kai Wang, Tingting Wu, Yanghua Tian, Juanjuan Zhan. Modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: Potential benefits of olanzapine. Schizophrenia research. Cognition. vol 36. 2024-03-12. PMID:38469136. |
in this behavioral study, we employed a lateralized version of the attention network test to examine the hemispheric asymmetry of executive control in schizophrenia patients before and after olanzapine treatment, compared to matched healthy controls. |
2024-03-12 |
2024-03-14 |
Not clear |
| Yong Zhao, Yifan Li, Jing Du, Chuanlong Fang, Wansheng Li, Mengyu Lv, Yue Wu, Kai Wang, Tingting Wu, Yanghua Tian, Juanjuan Zhan. Modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: Potential benefits of olanzapine. Schizophrenia research. Cognition. vol 36. 2024-03-12. PMID:38469136. |
these results suggested that olanzapine treatment may improve the efficiency of executive control in the left hemisphere in schizophrenia patients. |
2024-03-12 |
2024-03-14 |
Not clear |
| Cun Zhang, Lei Jiang, Ke Hu, Liang Chen, Yi-Jia Zhang, Hao-Zhe Shi, Su-Mei He, Xiao Chen, Dong-Dong Wan. Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients. Neuropsychiatric disease and treatment. vol 20. 2024-03-12. PMID:38469209. |
effects of aripiprazole on olanzapine population pharmacokinetics and initial dosage optimization in schizophrenia patients. |
2024-03-12 |
2024-03-14 |
Not clear |
| Cun Zhang, Lei Jiang, Ke Hu, Liang Chen, Yi-Jia Zhang, Hao-Zhe Shi, Su-Mei He, Xiao Chen, Dong-Dong Wan. Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients. Neuropsychiatric disease and treatment. vol 20. 2024-03-12. PMID:38469209. |
olanzapine has already been used to treat schizophrenia patients; however, the initial dosage recommendation when multiple drugs are used in combination, remains unclear. |
2024-03-12 |
2024-03-14 |
Not clear |
| Cun Zhang, Lei Jiang, Ke Hu, Liang Chen, Yi-Jia Zhang, Hao-Zhe Shi, Su-Mei He, Xiao Chen, Dong-Dong Wan. Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients. Neuropsychiatric disease and treatment. vol 20. 2024-03-12. PMID:38469209. |
the purpose of this study was to explore the drug-drug interaction (ddi) of multiple drugs combined with olanzapine and to recommend the optimal administration of olanzapine in schizophrenia patients. |
2024-03-12 |
2024-03-14 |
Not clear |
| Ying Liu, Xiaozhuang Ji. Fatty acid desaturase 1/2 (FADS1 and FADS2), fatty acid desaturase indices, and their relationships with metabolic syndrome in female adults with first-episode schizophrenia after antipsychotic medications. Psychoneuroendocrinology. vol 163. 2024-02-23. PMID:38394918. |
herein, we determined fatty acid desaturase 1 (fads1) and fads2 gene expressions, serum delta-5 desaturase (d5d) and d6d indices in female adults with first-episode schizophrenia after olanzapine medication, as well as their relationship with the incidence of mets. |
2024-02-23 |
2024-02-26 |
Not clear |
| Piaopiao Huang, Juanli Ran, Wenqiang Zhu, Wen Dai, Yaxin Tang, Pingan Lian, Xiansheng Huang, Rong L. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 38. issue 4. 2024-02-15. PMID:38358343. |
this highlights pcsk9 inhibitors as potential therapeutic agents for managing nafld in schizophrenia patients treated with olanzapine. |
2024-02-15 |
2024-02-17 |
mouse |
| Jed Hadjoudj, Catherine Feliu, Céline Konecki, Zoubir Djerad. Association between olanzapine plasma concentrations and treatment response: A systematic review, meta-analysis and individual participant data meta-analysis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 172. 2024-02-07. PMID:38325263. |
by meta-analysing pooled studies and available individual participant data, we aim to provide new insight on olanzapine therapeutic drug monitoring in schizophrenia. |
2024-02-07 |
2024-02-10 |
human |
| Mingwei Gao, Fuqi Wang, Chuanyao Sun, Shuzhuo Zhang, Ruibin S. Effects of olanzapine on hippocampal CA3 and the prefrontal cortex local field potentials. European journal of pharmacology. 2024-02-07. PMID:38325793. |
olanzapine is an antipsychotic drug applied in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders with similar or better improvement than haloperidol and risperidone in the treatment of depressive and negative symptoms. |
2024-02-07 |
2024-02-10 |
Not clear |
| Maiko Watanabe, Fuminari Misawa, Hiroyoshi Takeuch. Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study. Journal of clinical psychopharmacology. 2024-01-26. PMID:38277504. |
real-world effectiveness of high-dose olanzapine and clozapine for treatment-resistant schizophrenia in japan: a retrospective bidirectional mirror-image study. |
2024-01-26 |
2024-01-29 |
Not clear |
| Kyle D Medak, Stewart Jeromson, Annalaura Bellucci, Meagan Arbeau, David C Wrigh. Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine. iScience. vol 27. issue 1. 2024-01-08. PMID:38188526. |
olanzapine is a second-generation antipsychotic (ap) used in the management of schizophrenia. |
2024-01-08 |
2024-01-10 |
Not clear |
| Sanya Sharma, Ajeet Sidana, Shivangi Mehta, Manoj Kumar Baja. Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia. Indian journal of psychiatry. vol 65. issue 10. 2023-12-19. PMID:38108052. |
comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia. |
2023-12-19 |
2023-12-21 |
Not clear |
| Abdiweli Hassan, Mike Raschk. Avoiding a Poke: A Case Series of Intravenous Olanzapine in Pediatric Patients. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. vol 28. issue 8. 2023-12-14. PMID:38094671. |
although it was originally developed and approved for the treatment of various psychiatric conditions, such as schizophrenia and bipolar i disorder, recent studies have identified the role of olanzapine in the treatment of intensive care unit (icu)-related delirium and nausea and vomiting. |
2023-12-14 |
2023-12-17 |
Not clear |
| Weronika B Grywińska, Aleksandra Głowack. Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment. Postepy psychiatrii neurologii. vol 32. issue 3. 2023-11-30. PMID:38034507. |
combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment. |
2023-11-30 |
2023-12-10 |
Not clear |
| Weronika B Grywińska, Aleksandra Głowack. Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment. Postepy psychiatrii neurologii. vol 32. issue 3. 2023-11-30. PMID:38034507. |
this article analyzes clinical trials that provide evidence for the positive effects of using samidorphan to mitigate undesirable weight gain in patients diagnosed with schizophrenia who are undergoing treatment with olanzapine. |
2023-11-30 |
2023-12-10 |
Not clear |
| Kamisha L Johnson-Davis, Diane L. Quantification of Olanzapine by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods in molecular biology (Clifton, N.J.). vol 2737. 2023-11-30. PMID:38036836. |
olanzapine (zyprexa™) is indicated for the treatment of schizophrenia and bipolar disorder. |
2023-11-30 |
2023-12-10 |
Not clear |
| Zhenlei Peng, Qiyu Jia, Junxiong Mao, Qizhong Y. Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis. Neuropsychiatric disease and treatment. vol 19. 2023-11-01. PMID:37908559. |
effects of combined therapy of olanzapine and samidorphan on safety and metabolic parameters in schizophrenia patients: a meta-analysis. |
2023-11-01 |
2023-11-08 |
Not clear |